Overall, this study provided valuable insights into the effects of serum LCFA metabolism in psoriasis patients treated with anti-IL-17A mAb and emphasized the importance of targeted metabolic profiling in comprehending disease mechanisms. The gene discussed is IL17A; the disease is psoriasis.